Jump to content

Pharmacovigilance Agreements (PVAs):

Guidance on the quality oversight and operational aspects

Members click here to purchase


Non Members click on the buy it now link below



The purpose of this booklet is to provide some guidance on the quality oversight and operational aspects of PVAs for professionals working in PV, Legal, Regulatory Affairs and QA departments.

The booklet aims to provide you with:

•  An overview of the types of agreement
•  The items which you may need to consider when developing  and implementing PVAs
•  The items to consider and to prioritise for QA oversight
•  A matrix of the typical clauses according to your agreement type.



Types of agreements  

  • Co-development arrangements 
  • Co-Marketing and Licensing  
  • Distribution and Wholesaler Agreements 
  • Manufacturing arrangements 
  • Purchase agreements/tenders/charitable donations 
  • Service level agreements  
  • Business service providers for marketing related activities   
  • Service providers for delegated PV activities or PV supporting functions   
  • Collaboration arrangement with not-for-profit organisation

Operational aspects

Quality oversight

  • PVA Compliance 
  • Point to consider when developing a quality oversight strategy  
  • Methods of quality oversight 
  • Questionaire assessment 
  • Conclusions 


Sandra Dunlavy, Astellas
Magda Daudin, Janssen
Andrew Cooper, GlaxoSmithKline
Kieran O’Donnell, TMC Pharma Thomas Henn, United Therapeutics Europe Ltd

Tomoko Yanai, Santen Pharmaceutical Co., Ltd
Shigeo Suzuki, MSD K.K. Ayami Komatsu, Japan Tobacco INC.
Teiki Iwaoka, CAC Croit Corporation
Madoka Sasaki, Sumitomo Dainippon Pharma Co., Ltd. 


£10.00 RQA Members
£25.00 Non-Members